Targeted Oncology Staff

During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy.

During a Targeted Oncology case-based roundtable event, Erin Crane, MD, MPH, discussed several phase 3 trials of new combinations for maintenance therapy of advanced ovarian cancer.

During a Targeted Oncology case-based roundtable event, Rachel B. Salit, MD, discussed the case of a patient with acute graft versus host disease, steroid dependence, and therapy for steroid-refractory disease.

The FDA has granted approval to the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients with unresectable or metastatic melanoma.

During a live virtual event, Ruben Mesa, MD, discussed the use and sequencing of JAK inhibitors and stem cell transplant for patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Jad Chahoud, MD, MPH, discussed the case of a patient who progresses while on pembrolizumab plus axitinib, then again while on cabozantinib.

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the frontline treatment options for a patient with hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, David P. Carbone, MD, PhD, discussed molecular testing and treatment for a patient with late-stage non–small cell lung cancer.

During a live virtual event, Adam C. ElNaggar discussed with participants whether patients who respond to PARP inhibitors for advanced ovarian cancer should continue to receive them indefinitely.

During a Targeted Oncology case-based roundtable event, Luciano J. Costa, MD, PhD, discussed various treatment regiments for a patient with newly diagnosed multiple myeloma.

During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.

During a live virtual event, Pierre Gholam, MD, discussed treatment options for a patient with hepatocellular carcinoma who had serious medical conditions including cirrhosis, Crohn's disease, and variceal bleeding.

During a live virtual event, Philippe Armand, MD, PhD, discussed the results of the outcomes of clinical trials of tafasitamab plus lenalidomide as well as loncastuximab tesirine in diffuse large B-cell lymphoma.

During a live virtual event, Evan Yu, MD, discussed the choice of novel hormonal agent for a patient with nonmetastatic castration-resistant prostate cancer.

During a live virtual event, Sara Tolaney, MD, MPH, discussed the common issue of neutropenia in patients with triple-negative breast cancer who received sacituzumab govitecan in the ASCENT trial and in her clinical practice.

During a live virtual event, Adam C. ElNaggar, MD, discussed with participants their experiences with PARP inhibitors in patients with ovarian cancer.

During a live virtual event, Moshe Ornstein, MD, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and participants' experiences with these agents.

During a live virtual event, Daniel C. Danila, MD, discussed how to treat a patient with de novo metastatic castration-sensitive prostate cancer and monitor for disease progression.

During a Targeted Oncology case-based roundtable event, John M. Pagel, MD, PhD, discusses the case of a patient with diffuse large B-cell lymphoma who is not eligible for transplant.

During a Targeted Oncology case-based roundtable event, Scott Tykodi, MD, PhD, discussed the data supporting various treatment options for renal cell carcinoma with participants.

During a Targeted Oncology case-based roundtable event, Ruben Mesa, MD, discussed risk assessment and management of myeloproliferative neoplasms.

During a Targeted Oncology case-based roundtable event, Nasser H. Hanna, MD, discussed the results of the LIBRETTO-001, ARROW, and other trials of patients with lung cancer with RET mutations or other biomarkers.

During a live event, Evan Yu, MD, discussed how to monitor a patient being treated with androgen deprivation therapy and hormonal agents for nonmetastatic castration-resistant prostate cancer using prostate-specific antigen levels and next-generation imaging.

During a Targeted Oncology case-based roundtable event, Kenneth Shain, MD, PhD, discussed the case of a patient whose multiple myeloma progressed 1 year after treatment with daratumumab, bortezomib, and dexamethasone.

During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.

During a Targeted Oncology case-based roundtable event, Jennifer L. Atlas, MD, discussed the case of a patient with infiltrative basal cell carcinoma with participants.

During a Targeted Oncology case-based roundtable event, Rachel N. Grisham, MD, discussed clinical trials of different PARP inhibitors for patients with ovarian cancer.

During a Targeted Oncology case-based roundtable event, Uday R. Popat, MD, discussed the approaches to identifying and managing graft-vs-host disease.

During a Targeted Oncology case-based roundtable event, Roy S. Herbst, MD, PhD, and Joshua K. Sabari, MD, discussed molecular testing and the use of immune checkpoint inhibitors with participants.

During a Targeted Oncology live virtual event, Javier L. Munoz, MD, MBA, discussed third-line treatments for DLBCL including chimeric antigen receptor T-cell therapy and targeted treatments.